Skip to main content
Download PDF

Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial

BMC Cancer volume 22, Article number: 672 (2022) Cite this article

Abstract

Background

18F -fluorodeoxyglucose (FDG) positron emission tomography (PET) plays an important role in the staging and response assessment of lymphoma patients. Our aim was to explore the predictive relevance of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) in patients with early stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD16 trial.

Methods

18F-FDG PET/CT images were available for MTV and TLG analysis in 107 cases from the HD16 trial. We calculated MTV and TLG using three different threshold methods (SUV4.0, SUV41% and SUV140%L), and then performed receiver-operating-characteristic analysis to assess the predictive impact of these parameters in predicting an adequate therapy response with PET negativity after 2 cycles of chemotherapy.

Results

All three threshold methods analyzed for MTV and TLG calculation showed a positive correlation with the PET response after 2 cycles chemotherapy. The largest area under the curve (AUC) was observed using the fixed threshold of SUV4.0 for MTV- calculation (AUC 0.69 [95% CI 0.55–0.83]) and for TLG-calculation (AUC 0.69 [0.55–0.82]). The calculations for MTV and TLG with a relative threshold showed a lower AUC: using SUV140%L AUCs of 0.66 [0.53–0.80] for MTV and 0.67 for TLG [0.54–0.81]) were observed, while with SUV41% an AUC of 0.61 [0.45–0.76] for MTV, and an AUC 0.64 [0.49–0.80]) for TLG were seen.

Conclusions

MTV and TLG do have a predictive value after two cycles ABVD in early stage Hodgkin lymphoma, particularly when using the fixed threshold of SUV4.0 for MTV and TLG calculation.

Trial registration

ClinicalTrials.gov NCT00736320.

Peer Review reports

Background

Over the past few decades, Hodgkin lymphoma has become an effectively treatable malignancy with excellent long-term disease-free survival [1]. Nowadays, more than 90% of early-stage patients can be cured through first-line therapy, consisting of brief chemotherapy followed by 20 Gy consolidative irradiation [2,3,4,5]. Furthermore, treatment insensitivity in connection with both chemo- and radiotherapy has decreased considerably for patients with Hodgkin lymphoma at different tumor stages [6,7,8].

Since the introduction of 18F -fluorodeoxglucose (FDG) positron emission tomography (PET) into the management of many oncological diseases, it has taken on a major role in the staging and response assessment of lymphoma patients [9,10,11,12]. It has been shown that radiotherapy can safely be omitted in patients with PET-negative residual tissue after effective first-line chemotherapy for advanced-stage Hodgkin lymphoma [13]. Furthermore in advanced Hodgkin lymphoma, chemotherapy can be reduced to a total of 4 cycles eBEACOPP (Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone in escalated doses) if the PET is negative after 2 cycles [14]. For patients with early-stage unfavorable Hodgkin lymphoma, the HD17 trial has shown that radiotherapy can be omitted for PET-negative patients after effective chemotherapy without any clinically relevant loss of efficacy [15]. However, in early stage favorable Hodgkin lymphoma, three different randomized trials (H10, HD16 and RAPID) have shown that omitting radiotherapy in patients who are PET-negative after ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) chemotherapy is associated with a relevant loss of tumor control and increased number of relapses [6, 16, 17]. As the role of PET for individual tailoring of treatment is limited after 2 cycles of ABVD in early-stage favorable Hodgkin lymphoma, additional prognostic factors are needed urgently. Accordingly, we performed an analysis of metabolic tumor volume (MTV) and total lesion glycolysis (TLG) derived from PET at staging as potentially useful predictive factors, in early-stage Hodgkin lymphoma.

Methods

Study cohort

From November 2009 through December 2015, the prospective, multicenter phase III trial HD16 recruited a total of 1,150 therapy-naive Hodgkin lymphoma patients, aged 18 to 75 years. HD16 included patients in clinical stage I or II without risk factors such as three or more involved nodal areas, large mediastinal mass (≥ 1/3 of the maximal thoracic diameter as measured on chest X-ray), extra-nodal disease or elevated erythrocyte sedimentation rate (≥ 50 mm/h for patients without B symptoms and ≥ 30 mm/h in case of B symptoms).

In HD16, individuals were randomly assigned either to standard combined-modality treatment including 2 cycles of ABVD followed by PET (PET-2) and consolidating radiotherapy irrespective of PET-2 result, or to the experimental arm where irradiation was omitted in cases of PET negativity after 2 cycles of ABVD. In HD-16 PET-2 was mandatory for all patients, while a staging PET before start of treatment was not a mandatory part of the protocol. The PET scans were performed according to the respective national guidelines, which did not include SUV harmonization. Accordingly, our analysis set consisted of those 107 individuals with baseline PET (PET-0) images available to the central review panel for quantitative assessment. (Fig. 1).

Fig. 1
figure 1

Flow chart. 1150 patients included in the HD16 trial. Baseline 18F-FDG PET was centrally reviewed in 107 patients with quantitative analyses. Abbreviations: ITT, intention to treat. HL, Hodgkin lymphoma. MTV, metabolic tumor volume. TLG, total lesion glycolysis

Full size image

The HD16 trial was approved by the responsible ethics committees and was conducted according to the Declaration of Helsinki, in compliance with the Good Clinical Practice guidelines of the International Conference on Harmonization. All patients provided written informed consent before participation.

Image analysis

Baseline MTV and TLG were calculated in all baseline PET scans available for quantitative analyses, using the PET/CT Viewer in FIJI (ImageJ). First, maximal standardized uptake value (SUVmax) for the liver was obtained from a spherical 3-cm volume of interest (VOI) in the right liver lobe. Following that, SUVmax was estimated within all tumor sites with increased F-FDG uptake. Manual corrections were performed in cases where non-lymphoma tissue was included in the automatic calculation.

MTV calculations were then performed using the following thresholding methods:

  • 1. 41% of the SUVmax within the respective lymphoma site (MTV41%),

  • 2. a fixed SUV of 4.0 (MTV4.0),

  • 3. 140% of the SUVmax of liver background (MTV140%L).

Within these MTVs, SUVmean was estimated and TLG was calculated as the sum of supra-threshold voxels of all lymphoma lesions multiplied by SUVmean within the respective MTV as follows:

  • 1. Sum of MTV41% multiplied by SUVmean (TLG41%),

  • 2. Sum of MTV4.0 multiplied by SUVmean (TLG4.0),

  • 3. Sum of MTV140%L multiplied by SUVmean (TLG140%L),

Statistical evaluation

Patient characteristics and PET-2 response data were obtained from the study database. All data were analyzed descriptively. MTV and TLG distributions were visualized in histograms. The correlation of the different thresholding methods was assessed by Pearson product moment correlation coefficients. Receiver operating characteristic (ROC) analysis was performed to evaluate baseline MTV and TLG as predictors of PET-2 response, using the liver as cutoff for PET positivity (Deauville score 4) [18, 19]. Additionally, p-values resulting from logistic regressions on log-transformed data are reported to explore and quantify the predictive value of MTV and TLG on PET-2 positivity. All statistical computations were performed using SAS 9.4 (SAS Institute, Cary, NC, USA).

Results

Patients

Of the 1,139 patients from the intention-to-treat population of the HD16 study, 107 with available PET-0 were eligible for the present analysis. Characteristics of eligible and non-eligible patients are shown in Table 1. Among the 4 participating countries, the proportion of patients receiving a PET-0 scan was lowest in Germany. Other characteristics were similar in patients with and without PET-0. In PET-2, 16 (15%) of the patients examined were positive (Deauville Score 4) while 91 (85%) were negative (Deauville Score < 4).

Table 1 Patient characteristics
Full size table

MTV

Histograms of the MTV distributions are presented in Fig. 2 and show a right-skewed distribution for all thresholding methods. The median values of MTV41%, MTV4.0, and MTV140%L were 28.7 mL (range, 0.9 – 238.9), 27.4 mL (range, 0.34 – 397.8) and 24.4 mL (range, 0.1 – 386.4). The correlation between the two relative threshold methods was 0.70, while the correlations with the absolute thresholding method (MTV4.0) were 0.70 for MTV41% and 0.94 for MTV140%L, respectively. Low correlation of MTV41% might have been caused by the relatively lower volume compared to MTV4.0 and MTV140L in the case of a higher SUVmax.

Fig. 2
figure 2

Histograms of MTV distribution assessed by different thresholding methods. MTV was obtained using the following thresholds: 41% of the SUVmax within the respective lymphoma site (MTV41%), a fixed SUV of 4.0 (MTV4.0), and 140% of the SUVmax of liver background MTV140%L. Abbreviations: MTV, metabolic tumor volume

Full size image

TLG

Histograms of the TLG distributions are presented in Fig. 3 and show a right-skewed distribution for all thresholding methods. The SUVmean for MTV41% was 6.8 (± 3.2), MTV4.0 6.3 (± 1.8), and MTV140%L 6.6 (± 2.0). The median of TLG41%, TLG4.0, and TLG140%L were 162.0 (range, 5.8 – 2771.5), 160.5 (range, 1.4 – 3715.3) and 147 mL (range, 0.2 – 3670.8). The correlation between the two relative threshold methods was 0.94, while the correlations with the absolute thresholding method (TLG4.0) were 0.92 for TLG41% and 0.97 for TLG140%L, respectively.

Fig. 3
figure 3

Histograms of TLG distribution assessed by different thresholding methods. TLG was obtained using the following thresholds: 41% of the SUVmax within the respective lymphoma site (TLG41%), a fixed SUV of 4.0 (TLG4.0), and 140% of the SUVmax of liver background (TLG140%L). Abbreviations: TLG, total lesion glycolysis

Full size image

Effect of MTV on PET-2 positivity

The ROC curves for PET response after two cycles of ABVD were derived from MTV using different thresholding methods, and are displayed in Fig. 4. Areas under the curve (AUC) for MTV41%, MTV4.0, and MTV140%L were 0.61 (95% CI 0.45–0.76, Plogist = 0.29), 0.69 (0.55–0.83, Plogist = 0.031), and 0.66 (0.53–0.80, Plogist = 0.052).

Fig. 4
figure 4

ROC curves of MTV distribution assessed by different thresholding methods for PET response after two cycles of ABVD (16/107 = 15% PET-2-positive patients with Deauville score 4). MTV was obtained using the following thresholds: 41% of the SUVmax within the respective lymphoma site (MTV41%) a fixed SUV of 4.0 (MTV4.0) and 140% of liver background (MTV140%L). Abbreviations: MTV, metabolic tumor volume. AUC, area under the curve

Full size image

Effect of TLG on PET-2 positivity

The ROC curves for PET response after two cycles of ABVD were derived from TLG using different thresholding methods, and are displayed in Fig. 5. AUC for TLG41%, TLG4.0 and TLG140%L were 0.64 (95% CI 0.49–0.80, Plogist = 0.12), 0.69 (0.55–0.82, Plogist = 0.035), and 0.67 (0.54–0.81, Plogist = 0.052).

Fig. 5
figure 5

ROC curves of TLG distribution assessed by different thresholding methods for PET response after two cycles of ABVD (16/107 = 15% PET-2-positive patients with Deauville score 4). TLG was obtained using the following thresholds: 41% of the SUVmax within the respective lymphoma site (TLG41%) a fixed SUV of 4.0 (TLG4.0) and 140% of the SUVmax of liver background (TLG140%L). Abbreviations: TLG, total lesion glycolysis. AUC, area under the curve

Full size image

Discussion

The following results emerge from our analysis of 107 patients with early-stage favorable Hodgkin lymphoma: All three methods used for calculating MTV and TLG show a moderate predictive impact with regard to PET response after 2 cycles of ABVD in early-stage favorable Hodgkin lymphoma. Both the calculations of MTV and TLG using SUV 4.0 as fixed threshold, showed a small advantage, as compared to the other methods used.

Various studies have indicated the prognostic potential of baseline MTV in Hodgkin lymphoma patients [19,20,21,22,23,24,25,26]. Akhtari and colleagues showed that MTV and TLG could help predict worse outcome in 267 patients with early-stage Hodgkin lymphoma who received combined standard modality treatment. Furthermore, two distinct categories can be discerned from MTV or TLG: low and high disease burdens [20]. In a study of 59 patients with Hodgkin lymphoma treated with anthracycline-based chemotherapy, Kanoun and colleagues highlighted a possible division into two risk groups with regard to long-term success on the basis of the MTV and the metabolic signature [21]. Cottereau and colleagues showed baseline MTV to be a strong prognostic factor in 258 patients with early-stage Hodgkin lymphoma who received standard combined modality treatment. This collective of patients could also be divided into two risk groups based on the MTV [22]. In another group of 127 patients, Song and colleagues showed that MTV can be a prognostic factor and can also usefully influence selection of the necessary therapy regimen [23]. In 65 patients with a relapsed or refractory Hodgkin, Moskowitz and colleagues found MTV to be a very strong prognostic factor and one that can also improve the predictive value of PET before autologous stem cell transplantation [24]. In 310 patients with advanced Hodgkin lymphoma, Mettler and colleagues have shown that the MTV can predict patient response after two cycles of eBEACOPP, regardless of the method used to determine it [25]. The receiver-operating-characteristic curves in their study did not point to any unique cut-offs, but indicated a wide range of possible cut-offs [25], as we have also observed here in the present work. Analyzing a group of 140 DLBCL patients, Kim and colleagues show that the metabolic tumor burden expressed as TLG can be a prognostic factor for survival after R-CHOP [26]. All these studies are in line with our finding that initial MTV and TLG are parameters of additional use for response prediction.

Here, it should be noted that there is as yet no standardized procedure for measuring MTV and TLG [27]. A variety of methods and software platforms are currently in use for MTV and TLG calculation. The use of algorithms with fixed-threshold or relative-threshold values and adaptive threshold values is often encountered in this context [28]. Using a relative threshold of 41% of SUVmax for 106 patients with peripheral T-cell lymphoma, Cottereau and colleagues demonstrated that baseline MTV is a relevant risk factor [22]. Kanoun and colleagues showed that MTV calculation using a fixed threshold of SUV 2.5 gave a higher volume than a relative limit of 41% of SUVmax [21]. In their cohort of 140 DLBCL patients, Kim and colleagues showed that a TLG calculated with 50% of the SUVmax has the highest prognostic accuracy when a relative threshold is used [26]. This is contrary to our results that indicate that a fixed threshold has a higher predictive value than a relative threshold. Furthermore, in a group of 121 patients, Tutino and co-workers observed that with a fixed threshold of SUV4.0 MTV-calculation is less dependent on the reviewer and can be reproduced better than calculation using a relative threshold of SUV41% [29]. This is in line with our observation that MTV and TLG using a fixed cut-off of 4.0 may be slightly superior in terms of predicting PET-2 positivity. Here we have observed that MTV4.0 works comparably well in a cohort in which no SUV standardization between participating PET centers has been performed.

Due to the limited number of survival events, our analyses were restricted to PET-2 positivity and a further investigation of the influence on long-term efficacy in terms of progression-free survival is pending. However, as the prognostic influence of PET-2 on progression-free survival has been demonstrated for the HD16 trial [6], PET-2 could be regarded as a surrogate for longer-term efficacy. In order to further improve response prediction and risk-adapted individualization of therapy, additional risk factors are needed. Such risk factors might include but need not be restricted to the use of MTV and TLG, possibly in combination with PET-2. New biomarkers such as thymus and activation-regulated chemokine or cell free DNA would be well worth further investigation for individual tailoring of treatment in patients with Hodgkin lymphoma [30].

Conclusion

MTV and TLG show predictive value after two cycles of ABVD in early-stage favorable Hodgkin lymphoma. When determining MTV and TLG, due to higher reproducibility and a slight advantage over a relative threshold, we favor a fixed cut-off of SUV 4.0.

However, it remains to be shown whether these factors can have a useful impact on prognosis when applied in combination with PET-2 assessment and other biomarkers in early stage Hodgkin lymphoma.

Availability of data and materials

From the corresponding author on request.

Abbreviations

FDG:

18F -fluorodeoxyglucose

PET:

Positron emission tomography

CT:

Computed tomography

MTV:

Metabolic tumor volume

TLG:

Total lesion glycolysis

AUC:

Area under the curve

SUV:

Standardized uptake value

ABVD:

Adriamycin, Bleomycin, Vinblastin und Dacarbazin

Gy:

Gray

GHSG:

German Hodgkin Study Group

PET-0:

Baseline PET

PET-2:

PET after 2 cycles of chemotherapy

VOI:

Volume of interest

ROC:

Receiver operating characteristic

eBEACOPP:

Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine and Prednisone in escalated doses

DLBCL:

Diffuse large B cell lymphoma

R-CHOP:

Rituximab, Clophosphamid; Doxorubicin; Vincristin; Prednisone

References

  1. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review. 1975–2016. https://seer.cancer.gov/csr/1975_2016/. Accessed 7 Nov 2021.

  2. Fermé C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin’s disease. N Engl J Med. 2007;357:1916–27.

    Article  Google Scholar 

  3. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med. 2010;363:640–52.

    Article  CAS  Google Scholar 

  4. Connors JM. State-of-the-art therapeutics: Hodgkin´s lymphoma. J Clin Oncol. 2005;23:6400–8.

    Article  CAS  Google Scholar 

  5. Engert A, Horning S, editors. Hodgkin Lymphoma. Heidelberg: Springer; 2011.

    Google Scholar 

  6. Fuchs M, Goergen H, Kobe C, et al. Positron emission tomography-guided treatment in early-stage favorable Hodgkin Lymphoma: final results of the international, radomized phase II HD16 trial by the German Hodgkin Study Group. J Clin Oncol. 2019;37(31):2835–45.

    Article  CAS  Google Scholar 

  7. Eichenauer DA, André M, Johnson P, et al. Controversies in the treatment of classical Hodgkin Lymphoma. Hemasphere. 2008;2(5):e149.

    Article  Google Scholar 

  8. Engert A, Younges A (eds): Principles of radiation therapy for Hodgkin Lymphoma in Hodgkin Lymphoma: a comprehensive overview. Basel: Springer International Publishing; 2015. p. 157–77.

  9. Kobe C, Dietlein M, Franklin J, et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced stage Hodgkin lymphoma. Blood. 2008;112:3989–94.

    Article  CAS  Google Scholar 

  10. Weihrauch MR, Re D, Bischoff S, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for initial staging of patients with Hodgkin´s disease. Ann Hematol. 2002;81:20–5.

    Article  CAS  Google Scholar 

  11. Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin´s disease. Haematologica. 2006;91:475–81.

    PubMed  Google Scholar 

  12. Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin´s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25:3746–52.

    Article  CAS  Google Scholar 

  13. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and-guided radiptheray in patients with advanced stage Hodgkin´s lymphoma (HD15 trial): a randomized, open label phase 3 non-inferiority trial. Lancet. 2012;379:1791–9.

    Article  CAS  Google Scholar 

  14. Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin´s lymphoma (HD18): final results of an open-label, international, randomized phase 3 trial by the German Hodgkin Study Group. Lancet. 2017;390:2790–802.

    Article  Google Scholar 

  15. Borchman P, Plütschow A, Kobe C, et al. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicenter, open-label, randomized, phase 3 trial. Lancet Oncol. 2021;22(2):223–34.

    Article  Google Scholar 

  16. Raemaekers JMM, André MPE, Federico M, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relaps: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 Trial. J Clin Oncol. 2014;32(12):1188–94.

    Article  Google Scholar 

  17. Radford J, Illidge T, Counsell N, et al. Results of trial of PET-directed therapy for early-stage Hodgkin´s lymphoma. N Engl J Med. 2015;372:1598–607.

    Article  CAS  Google Scholar 

  18. Meignan M, Cottereau AS, Versari A, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: apooled analysis of three multicentre studies. J Clin Oncol. 2016;34:3618–26.

    Article  Google Scholar 

  19. Gallamini A, Barrington SF, Biggi A, et al. The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five point scale. Haematologica. 2014;99:1107–13.

    Article  Google Scholar 

  20. Akhtari M, Milgrom SA, Pinnix CC, et al. Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. Blood. 2018;131:84–94.

    Article  CAS  Google Scholar 

  21. Kanoun S, Rossi C, Berriolo-Riedinger A, et al. Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2014;41:1735–43.

    Article  Google Scholar 

  22. Cottereau AS, Versari A, Loft A, et al. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood. 2018;131:1456–63.

    Article  CAS  Google Scholar 

  23. Song MK, Chung JS, Lee JJ, et al. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin’s lymphoma. Cancer Sci. 2013;104:1656–61.

    Article  CAS  Google Scholar 

  24. Moskowitz AJ, Schoder H, Gavane S, et al. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Leuk Lymphoma. 2009;50:1257–60.

    Article  Google Scholar 

  25. Mettler J, Müller H, Voltin CA, et al. Metabolic tumor volume for response prediction in advance-stage Hodgkin Lymphoma. J Nucl Med. 2019;60:207–11.

    Article  CAS  Google Scholar 

  26. Kim TM, Paeng JC, Chun IK, et al. Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the international prognostic index for patients with diffus lage B Cell lymphoma. Cancer. 2013;119(6):1195–202.

    Article  CAS  Google Scholar 

  27. Meignan M, Sasanelli M, Casasnovas RO, et al. Metabolic tumour volumes measured at staging in lymphoma: Methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging. 2014;41:1113–22.

    Article  CAS  Google Scholar 

  28. Carlier T, Bailly C. State-of-theart and recent advances in quantification for therapeutic follow-up in oncology using PET. Front Med. 2015;2:18.

    Article  Google Scholar 

  29. Tutino F, Puccini G, Linguanti F, et al. Baseline metabolic tumor volume calculation using different SUV thresholding methods in Hodgkin Lymphoma patients: interobserver argreement and reproducibility across software platforms. Nuc Med Com. 2021;42(3):284–91.

    Article  CAS  Google Scholar 

  30. Borchmann S. Liquid biopsy in Hodgkin lymphoma – moving beyond the proof of principle. Br J Haematol. 2021;195(4):493–4.

    Article  Google Scholar 

Download references

Acknowledgements

Not applicable

Funding

Open Access funding enabled and organized by Projekt DEAL. No specific funding for this study.

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Kerpener Straße 62, 50937, Cologne, Germany

    Lutz van Heek, Colin Stuka, Jasmin Mettler, Markus Dietlein, Conrad-Amadeus Voltin & Carsten Kobe

  2. First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

    Helen Kaul, Horst Müller, Michael Fuchs, Peter Borchmann & Andreas Engert

  3. Swiss Group for Clinical Cancer Research, Bern, Switzerland

    Felicitas Hitz

  4. Department of Medical Oncology and Haematology, Kantonsspital St.Gallen, St. Gallen, Switzerland

    Felicitas Hitz

  5. Department of Radiation Oncology and Cyberknife Center, Faculty of Medicine and UniversityHospital Cologne, University of Cologne, Cologne, Germany

    Christian Baues

Authors
  1. Lutz van Heek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Colin Stuka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Helen Kaul
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Horst Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jasmin Mettler
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Felicitas Hitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Christian Baues
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Michael Fuchs
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Peter Borchmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Andreas Engert
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Markus Dietlein
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Conrad-Amadeus Voltin
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Carsten Kobe
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conception and design: LvH, CS, JM, MF, PB, AE, MD, CK. Provision of study materials or patients: LvH, CS, JM, FH, MF, PB, AE, CK. Collection and assembly of data: LvH, CS, JM, FH, CB, MF, PB, AE, MD, CAV, CK. Data analysis and interpretation: LvH, CS, HK, HM, JM, CB, MF, PB, AE, MD, CAV, CK. Manuscript writing: All authors. Final approval of manuscript: All authors. Accountable for all aspects of the work: All authors.

Corresponding author

Correspondence to Lutz van Heek.

Ethics declarations

Ethics approval and consent to participate

The study was ethically approved by the ethical review committee of the Medical Faculty of the University of Cologne. All patients gave their written consent to participate in the HD16 trial.

Consent for publication

Not applicable.

Competing interests

All authors declare that they have no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

van Heek, L., Stuka, C., Kaul, H. et al. Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial. BMC Cancer 22, 672 (2022). https://doi.org/10.1186/s12885-022-09758-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12885-022-09758-z

Keywords

  • Hodgkin lymphoma
  • Metabolic tumor volume
  • FDG PET
  • Response prediction

BMC Cancer

ISSN: 1471-2407

Contact us